May 18, 2013
The future of Indiana’s sprawling health care and life sciences industry might be threatened by an unlikely source:
smartphone apps.
More.
May 17, 2013
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues
of venture capital, digital health innovations and research university entrepreneurship.
Panel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor
of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president,
CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy,
PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.
The following is an unedited transcript of the discussion.More.
May 16, 2013
Eli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major
developed countries.
More.
Back to Top
Generic Zyprexa (Olanzapine) still a cash cow for Lilly. Well, Lilly did make an astounding $70 billion to date on Zyprexa and sales off-patent are still at $2 billion year.Not a bad hunk of change.-Daniel Haszard Zyprexa patient who got diabetes from it's side effect
Obamacare is destroying medical device jobs which are now likely to go overseas. Why stay in the US if you don't have this tax when you relocate our of the country?
The device makers are just blowing smoke. Look at Zimmers financials: The $50MM is only 6.6% of their net income for 2012. They note the 43% of cash flow but they bought back $438MM in stock. It is like a small sales tax - it is minuscule in the grand scheme - they are just crying.